1. Guidance for industry: dissolution testing of immediate release solid oral dosage forms. U.S. Department of Health, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), August, 1997.
2. Guidance for industry: extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations. U.S. Department of Health, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), September, 1997.
3. Note for guidance on development pharmaceutics; European agency for the evaluation of medicinal products. Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products, CPMP/QWP/155/96; London, January 1998.
4. Note for guidance on modified release oral and transdermal dosage forms: section II (Pharmacokinetic and Clinical Evaluation). European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products, CPMP/EWP/280/96, London, July 1999.
5. Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), (EMA/CPMP/EWP/280/96 Corr1). London, November 2014.